Conditions: Migraine
Keywords: Migraine Triptans Motion Sickness
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 36
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine if Rizatriptan, a migraine medication, lowers motion sickness in migraine sufferers.

Detailed description:
Migraine sufferers undergo vestibular tests and were excluded if there were clinically significant abnormalities. Following screening, there were 2 experimental visits in which migraine sufferers were pre-treated with either Rizatriptan or placebo. After taking the drug, subjects were idle for 2 hours. Baseline motion sickness and subjective units of distress levels were assessed prior to undergoing sinusoidal-earth-vertical earth axis rotation in darkness at 0.05 Hz. Scores were taken immediately after stopping. Subjects were given a 2 minutes rest and then underwent a motion sickness provoking rotation. Subjective scores were assessed immediately following. Another two minute rest was given and if the subject was able, underwent a second motion sickness provoking stimulus followed by an assessment.

Arms:
arm 1: This group received placebo on visit 1 and Rizatriptan on visit 2. arm 2: These subjects received Rizatriptan on visit 1 and placebo on visit 2. arm 3: This group received placebo on visit 1 and Rizatriptan on visit 2. arm 4: This group received Rizatriptan on visit 1 and placebo on visit 2.

Interventions: intervention 1: Rizatriptan intervention 2: Placebo
Intervention descriptions: intervention 1: 10 mg Rizatriptan in an unlabeled pill given once on one of two visits intervention 2: In an unlabeled pill given once on one of two visits.

Protocol document: